Cargando…

Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data

PURPOSE: Measures derived from longitudinal tumour size data have been increasingly utilised to predict survival of patients with solid tumours. The aim of this study was to examine the prognostic value of such measures for patients with metastatic pancreatic cancer undergoing gemcitabine therapy. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wendling, Thierry, Mistry, Hitesh, Ogungbenro, Kayode, Aarons, Leon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844653/ https://www.ncbi.nlm.nih.gov/pubmed/26940939 http://dx.doi.org/10.1007/s00280-016-2994-x

Ejemplares similares

Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation
por: Lombard, Aurélie, et al.
Publicado: (2020)

A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models
por: Yau, Estelle, et al.
Publicado: (2023)

Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway
por: Hodson, David, et al.
Publicado: (2023)

Investigation of simplified physiologically‐based pharmacokinetic models in rat and human
por: Yau, Estelle, et al.
Publicado: (2023)

Development and validation of a methotrexate adherence assay
por: Bluett, James, et al.
Publicado: (2019)

On the relationship between tumour growth rate and survival in non-small cell lung cancer
por: Mistry, Hitesh B.
Publicado: (2017)

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
por: Cleary, Yumi, et al.
Publicado: (2021)

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
por: Mistry, Hitesh B., et al.
Publicado: (2017)

Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells
por: Smith, P. L., et al.
Publicado: (2020)

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
por: Cleary, Yumi, et al.
Publicado: (2023)

Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study
por: Galea, James, et al.
Publicado: (2011)

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics
por: Mistry, Hitesh B., et al.
Publicado: (2019)

SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
por: Bianconi, Daniela, et al.
Publicado: (2018)

A simple model of a growing tumour
por: Orrell, David, et al.
Publicado: (2019)

Impact of tumour size on metastasis and survival in patients with pancreatic neuroendocrine tumours (PNETs): A population based study
por: Liu, Yangyang, et al.
Publicado: (2019)

The role of gemcitabine in the treatment of other tumours.
por: Carmichael, J.
Publicado: (1998)

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
por: Hamada, T, et al.
Publicado: (2014)

Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
por: Chen, Yang, et al.
Publicado: (2017)

Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine
por: Huang, Xudong, et al.
Publicado: (2018)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy
por: Yang, Shih-Hung, et al.
Publicado: (2017)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma
por: Ellsworth, Katarzyna A., et al.
Publicado: (2013)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model
por: Yehya, Ashwaq Hamid Salem, et al.
Publicado: (2022)

Predictive Modeling of In Vivo Response to Gemcitabine in Pancreatic Cancer
por: Lee, James J., et al.
Publicado: (2013)

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

A Ketogenic Diet in Combination with Gemcitabine Increases Survival in Pancreatic Cancer KPC Mice
por: Cortez, Natalia E., et al.
Publicado: (2022)

The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer
por: Goto, Koki, et al.
Publicado: (2018)

Does “Birth” as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full‐Term Neonates by Avoiding the Creatinine Bias
por: Salem, Farzaneh, et al.
Publicado: (2020)

Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis
por: Goulart, Bernardo HL, et al.
Publicado: (2009)

Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
por: Halm, U, et al.
Publicado: (2000)

Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy
por: Hill, R, et al.
Publicado: (2013)

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
por: Gravett, A. M., et al.
Publicado: (2018)

Gemcitabine plus nab‐paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study
por: Saito, Kei, et al.
Publicado: (2023)

Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer
por: Sivapalan, Lavanya, et al.
Publicado: (2022)

Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy
por: Chao, Ying-Jui, et al.
Publicado: (2014)

The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance
por: Elaskalani, Omar, et al.
Publicado: (2017)

Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells
por: Kim, Myoungjae, et al.
Publicado: (2019)

Correction: A Ketogenic Diet in Combination with Gemcitabine Increases Survival in Pancreatic Cancer KPC Mice
por: Cortez, Natalia E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_khlcceatjaiohe4shft83t20qu